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In a prospective cohort of 534 neonates with acute symptomatic seizures, 66%
had incomplete response to the initial loading dose of antiseizure medication
(ASM). Treatment response did not differ by gestational age, sex, medication, or
dose. The risk of incomplete response was highest for seizures due to intracranial
hemorrhage and lowest for hypoxic‐ischemic encephalopathy, although the differ-
ence was not significant after adjusting for high seizure burden and therapeutic
hypothermia treatment. Future trial design may test ASMs in neonates with all
acute symptomatic seizure etiologies and could target neonates with seizures
refractory to an initial ASM.
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1 | INTRODUCTION
Acute symptomatic neonatal seizures are often refractory to
first‐line antiseizure medications (ASMs). In the 1999 clini-
cal trial of phenobarbital versus phenytoin, seizures
recurred in >50% of neonates following the first loading
dose of either medication, and neonates with higher seizure
burden were less likely to respond.1 Little is known about
additional characteristics associated with initial treatment
failure, although we previously showed that preterm and
term neonates were equally likely to have persistent sei-
zures after a loading dose of phenobarbital2 and there was
no difference in treatment response to initial doses of phe-
nobarbital, phenytoin, or levetiracetam as the first‐line
ASM.3
We hypothesized that treatment response to ASMs
would not differ by seizure etiology and that treatment
response would be dose dependent. Confirming these
hypotheses provides important evidence for clinical care
and data to inform future clinical trial design.
2 | MATERIALS AND METHODS
This prospective, observational cohort study included neo-
nates with acute symptomatic seizures due to hypoxic‐
ischemic encephalopathy (HIE), ischemic stroke (arterial or
venous), or intracranial hemorrhage (ICH) treated at the
nine sites of the Neonatal Seizure Registry (NSR). Each
site has a level IV neonatal intensive care unit and follows
the American Clinical Neurophysiology Society (ACNS)
guidelines for continuous electroencephalography (cEEG)
in neonates.4
Two prospective cohorts were merged: (1) NSR, a
consecutive cohort of all neonates with seizures diag-
nosed clinically and/or with EEG confirmation enrolled
January 2013 to November 2015 (waiver of consent);
and (2) NSR‐II, a nonconsecutive cohort of neonates
with acute symptomatic seizures diagnosed clinically and/
or with EEG confirmation enrolled from July 2016 to
March 2018 who survived the neonatal hospital admis-
sion (required written parental informed consent). The
local institutional review board for every site approved
the studies. Neonates from the initial NSR cohort were
previously reported.2,3,5
Neonates were included if they received a loading dose
of an ASM and adequate documentation regarding response
to the loading dose was available. Neonates with events
that were determined not to be seizures based on history,
semiology, or cEEG were not enrolled. Inclusion of neo-
nates with clinical events suspected to be seizures but with-
out seizures confirmed on the study site EEG was at the
discretion of the site investigator and considered if (1)
events were treated with ASMs; and (2) the clinical history,
event semiology, or referring hospital EEG supported the
diagnosis of seizures. Study site investigators determined
the primary seizure etiology based upon systematic medical
record review. A neonate was considered to have incom-
plete response if electrographic seizures were documented
>30 minutes after the initial load of medication was com-
plete. The data collected could not be used to differentiate
between incomplete and absent response to ASMs.
Seizures were defined as sudden, abnormal EEG events
with repetitive and evolving pattern with minimum ampli-
tude of 2 μV and duration ≥ 10 seconds and were not
required to have a clinical correlate.6 Seizure exposure was
extracted from cEEG reports at the study center and was
categorized as follows: (1) high burden: status epilepticus,
frequent recurrent seizures without status epilepticus, many
(≥7) isolated seizures; and (2) low burden: <7 seizures.7
Seizure treatment, including ASM selection and deter-
mination of loading dose, was at the discretion of the pro-
vider. No study‐specific treatment guideline was provided,
although seven of the nine sites had institutional guidelines,
pathways, or workflows for seizure management. Initial
EEG background was determined by the study site investi-
gator based on the EEG report available for 253 neonates
and was categorized as (1) normal or (2) abnormal (includ-
ing burst suppression).
Descriptive statistics and results of t tests and chi‐
squared tests are presented. Multivariate logistic regression
was used to build an adjusted model (initial inclusion
P ≤ 0.1, final model inclusion adjusted P < 0.1). EEG
background was only available for a subset of participants
and therefore was not included in the analysis. Confidence
intervals (CIs) were calculated using pairwise comparison
of 95% CIs. Analyses were completed using Stata 14
(StataCorp).
3 | RESULTS
From January 2013 to March 2018, 534 neonates were
enrolled (five neonates were excluded for unknown loading
dose, one for unknown response, one for initial medication
not known). EEG recording duration was a median of 72
(interquartile range = 45.7‐99.3) hours. Table 1 presents
the patient characteristics. Overall, 354 neonates (66%) had
an incomplete response to the initial loading dose of ASM.
There was no significant difference in the response by
treating institution (P = 0.2), although the range was broad
(56%‐81%); 95% CIs suggested at most a difference of
52% between the highest and lowest centers with incom-
plete response.
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3.1 | Clinical risk factors for incomplete
response
Incomplete response to the first loading dose of ASM was
highest for neonates with seizures due to ICH (82/
108 = 76%), as compared with HIE (175/284 = 62%) and
stroke (97/142 = 68%, P = 0.02). There was no significant
difference by sex (male 203/306 = 66% vs female 151/
228 = 66%, P = 0.98).
When comparing gestational age (GA) at birth, incom-
plete response was highest for extremely preterm neonates
(13/16 = 81% for extremely preterm [<28 weeks GA] vs
6/12 = 50% for very preterm [28 to <32 weeks GA] vs 30/
51 = 59% for moderate/late preterm [32 to <37 weeks
GA] vs 305/455 = 67% for term [≥37 weeks GA]); how-
ever, the differences were not significant (P = 0.2).
There was a higher chance of incomplete response to the
initial dose of medication for neonates with higher electroen-
cephalographic seizure exposure (status epilepticus, 97/
100 = 96%; frequent recurrent seizures, 125/140 = 89%; ≥7
isolated seizures, 72/94 = 72%; <7 seizures, 60/198 = 30%;
P < 0.0005), although it was unknown how many seizures
occurred before versus after ASM initiation.
Among term neonates with HIE, those who were not
treated with therapeutic hypothermia were more likely to
have an incomplete response than those who were cooled
(78/105 = 74% among those not treated with therapeutic
hypothermia vs 77/143 = 54% among those who were,
P < 0.001).
3.2 | Treatment response by ASM
Phenobarbital was the initial loading medication for 95% of
participants. Incomplete response to the initial loading dose
of the ASMs was similar (phenobarbital, 336/508 = 66%;
levetiracetam, 14/21 = 67%; fosphenytoin, 4/5 = 80%;
P = 0.8); however, the number of neonates who received
levetiracetam or fosphenytoin was very small. Difference in
response by initial ASM was at most 49% using 95% CIs,
with fosphenytoin performing worst.
There was no significant difference in loading dose
measured in milligrams per kilogram for phenobarbital
(mean loading dose was 19.9 ± 4.4 mg/kg with incomplete
response vs 19.3 ± 3.2 mg/kg for neonates with complete
response, P = 0.096). Similarly, there was no significant
difference for levetiracetam (34.5 ± 18.0 mg/kg with
incomplete response vs 24.5 ± 5.7 mg/kg with complete
response, P = 0.2) and fosphenytoin (20.0 ± 4 mg/kg for
neonates with incomplete response vs 20.0 mg/kg for the
single neonate with complete response, P > 0.99; Figure 1);
however, the numbers of neonates who received levetirac-
etam and fosphenytoin was very small.
3.3 | Relationship between EEG background
and treatment response
Among 253 neonates with cEEG background reports avail-
able for analysis, the risk of incomplete response was
higher for those with abnormal interictal EEG (159/
234 = 68%) as compared to those with normal interictal
EEG (9/19 = 47%, relative risk = 1.4, 95% CI = 0.9‐2.3,
P = 0.07).
3.4 | Multivariate analysis
After adjusting for high seizure burden and therapeutic
hypothermia, seizure etiology was no longer significantly
associated with likelihood of response to ASM (ICH odds
ratio [OR] = 1.5, 95% CI = 08‐2.6 and ischemic stroke
OR = 0.8, 95% CI = 0.5‐1.5 when compared with HIE,
P = 0.2), whereas high seizure burden (OR = 15.9, 95%
CI = 10.1‐25.0, P < 0.0005) and therapeutic hypothermia
(OR = 0.5, 95% CI = 0.3‐0.9, P = 0.01) remained very
highly associated with ASM response.
4 | DISCUSSION
In this large, prospective, multicenter study of neonates
with acute symptomatic seizures due to the three most
common neonatal seizure etiologies (HIE, ischemic stroke,
or ICH), the rate of incomplete response to the first loading
dose of ASM was very high (66%). Risk factors for incom-
plete response included lack of therapeutic hypothermia
treatment and high electrographic seizure burden.
It has been 20 years since a trial of phenobarbital versus
phenytoin for initial neonatal seizure management reported
that standard loading doses control seizures in fewer than
TABLE 1 Clinical characteristics of 534 prospectively enrolled
infants with acute symptomatic neonatal seizures




Hypoxic‐ischemic encephalopathy 284 (53%)
Ischemic stroke 142 (27%)
Intracranial hemorrhage 108 (20%)




Data are presented as n (%).
ASM, antiseizure medication.
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half of infants.1 Since then, more than 15 new ASMs have
come to market for epilepsy management. Many new drugs
are not suitable for critically ill neonates, yet even ASMs
that may be appropriate (ie, drugs with intravenous formu-
lations such as levetiracetam, lacosamide, and brivarac-
etam) have not been studied in neonates in published
randomized and controlled clinical trials. Case reports and
case series of levetiracetam have established pharmacoki-
netics8,9 and suggest that it is safe and may be effective for
newborns with seizures.9–11 A clinical trial of phenobarbital
versus levetiracetam is complete, but the results have not
yet been published. Animal studies of bumetanide com-
bined with phenobarbital as a rational synergistic therapy
show some promise; however, a small clinical trial was
inconclusive.12
Barriers to neonatal seizure treatment trials include rel-
atively rare incidence of the condition; the need for rapid
consent, enrollment, and randomization; lack of wide-
spread cEEG availability; and uncertainty regarding opti-
mal outcome measures. Clinical trials are needed not only
to determine the most effective ASM and dose but also
to examine treatment approaches. Such approaches include
the value and optimal use of cEEG and determining
whether speed of effective treatment influences seizure
response or long‐term neurodevelopmental and epilepsy
outcomes. Our results suggest that, in planning efficient
neonatal clinical trials of ASMs, investigators could con-
sider broad entry criteria (eg, including late preterm
infants, as well as neonates with HIE, ischemic stroke,
and ICH) but might need to stratify by therapeutic
hypothermia treatment, pretreatment seizure burden, and
initial EEG background. Our data underscore the need to
test new medications in neonates with seizures refractory
to an initial ASM, who are the majority of those with sei-
zures, who usually have a higher seizure burden, and in
whom improved treatment is more likely to have an
impact on long‐term outcome.
Although we present a large, multicenter cohort, our
data have limitations. First, our NSR‐II cohort excluded
children who died during the neonatal admission and
included nonconsecutive neonates. Therefore, it may be
enriched for less severely affected infants. Second, incom-
plete response to ASM was defined as seizure recurrence
>30 minutes after the initial loading dose. Although most
treatment failures occur within the first few hours after a
loading dose of ASMs, we cannot exclude that seizures
recurred >24 hours after the loading dose given that study
sites monitored neonates for a minimum of 24 hours after
the last electroencephalographic seizure as per ACNS
guidelines. Third, seizure exposure was measured using
counts rather than other approaches (eg, percentage of the
record comprised of seizures). Fourth, seizure exposure
prior to the medication load was not universally available,
so we cannot differentiate between seizures occurring
before and after the initial loading dose; however, our find-
ings are in keeping with the results of the Painter trial,1
which also showed a relationship between seizure burden
and response to ASM. Fifth, the time from seizure recogni-
tion to treatment was not measured, and this timing might
modify treatment response. Sixth, use of ASMs was not
randomized, and therefore it is difficult to interpret any
similarities or differences by ASM.
5 | CONCLUSIONS
Incomplete response to ASM is expected for most neonates
with acute symptomatic seizures who receive current stan-
dard treatment approaches, regardless of etiology, GA, ini-
tial ASM, and loading dose. This finding underscores the
need for novel treatment approaches and suggests that
future trials focused on ASM efficacy may be efficiently
designed by stratification or exclusion of lower‐risk groups
and could include all acute symptomatic etiologies of
FIGURE 1 Response to antiseizure medication for 534 neonates with acute symptomatic seizures stratified by medication and dose.
Response did not vary by medication (incomplete responses: phenobarbital, 336/508 = 66%; levetiracetam, 14/21 = 67%; fosphenytoin, 4/
5 = 80%; P = 0.8)
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seizures, particularly those with seizures refractory to an
initial ASM.
ACKNOWLEDGMENTS
The Pediatric Epilepsy Research Foundation and the Patient
Centered Outcomes Research Institute supported this study
but did not participate in design or conduct of the study;
collection, management, analysis, or interpretation of the
data; preparation, review, or approval of the manuscript; or
the decision to submit the manuscript for publication. The
authors thank Drs Donna Ferriero and Faye Silverstein for
their contributions to the NSR, as well as the research
assistants and parent partners at each study site.
DISCLOSURE OF CONFLICT OF INTEREST
J.S.S. receives royalties from UpToDate. C.J.W. has served
as a paid consultant for Ceribell and Persyst. M.R.C.
received research funding from Insys Development Com-
pany, paid to her Institution, for company sponsored trials;
she has been a consultant for BioMarin Research and for
GW Pharmaceuticals. R.A.S. is a consultant for the Epi-
lepsy Study Consortium and receives honoraria from
UpToDate for neonatal seizures topics. None of the other
authors has any conflict of interest to disclose. We confirm
that we have read the Journal's position on issues involved
in ethical publication and affirm that this report is consis-
tent with those guidelines.
ORCID
Hannah C. Glass https://orcid.org/0000-0002-3879-1966
Renée A. Shellhaas https://orcid.org/0000-0002-3175-
3908
REFERENCES
1. Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared
with phenytoin for the treatment of neonatal seizures. N Engl J
Med. 1999;341:485–9.
2. Glass HC, Shellhaas RA, Tsuchida TN, et al. Seizures in preterm
neonates: a multicenter observational cohort study. Pediatr Neu-
rol. 2017;72:19–24.
3. Shellhaas RA, Chang T, Wusthoff CJ, et al. Treatment duration
after acute symptomatic seizures in neonates: a multicenter cohort
study. J Pediatr. 2017;181:298–301.e1.
4. Shellhaas RA, Chang T, Tsuchida T, et al. The American clinical
neurophysiology society's guideline on continuous electroen-
cephalography monitoring in neonates. J Clin Neurophysiol.
2011;28:611–7.
5. Glass HC, Shellhaas RA, Wusthoff CJ, et al. Contemporary pro-
file of seizures in neonates: a prospective cohort study. J Pediatr.
2016;174:98–103.
6. Tsuchida TN, Wusthoff CJ, Shellhaas RA, et al. American Clini-
cal Neurophysiology Society standardized EEG terminology and
categorization for the description of continuous EEG monitoring
in neonates: report of the American Clinical Neurophysiology
Society Critical Care Monitoring Committee. J Clin Neurophysiol.
2013;30:161–73.
7. Glass HC, Shellhaas RA, Wusthoff CJ, et al. Contemporary pro-
file of seizures in neonates: a prospective cohort study. J Pediatr.
2016;174:98–103.e1.
8. Merhar SL, Schibler KR, Sherwin CM, et al. Pharmacokinetics of
levetiracetam in neonates with seizures. J Pediatr. 2011;159:152–
4.e3.
9. Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ,
Haas RH. A seven‐day study of the pharmacokinetics of intra-
venous levetiracetam in neonates: marked changes in pharmacoki-
netics occur during the first week of life. Pediatr Res.
2012;72:43–9.
10. Abend NS, Gutierrez-Colina AM, Monk HM, Dlugos DJ, Clancy
RR. Levetiracetam for treatment of neonatal seizures. J Child
Neurol. 2011;26:465–70.
11. Rakshasbhuvankar A, Rao S, Kohan R, Simmer K, Nagarajan L.
Intravenous levetiracetam for treatment of neonatal seizures. J
Child Neurol. 2013;20:1165–7.
12. Pressler RM, Boylan GB, Marlow N, et al. Bumetanide for the
treatment of seizures in newborn babies with hypoxic ischaemic
encephalopathy (NEMO): an open‐label, dose finding, and feasi-
bility phase 1/2 trial. Lancet Neurol. 2015;14:469–77.
How to cite this article: Glass HC, Soul JS, Chu
CJ, et al. Response to antiseizure medications in
neonates with acute symptomatic seizures. Epilepsia.
2019;60:e20–e24. https://doi.org/10.1111/epi.14671
e24 | GLASS ET AL.
